gdc
Breast CancerFDA Approvals, News & UpdatesNewsworthy

Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
December 2017 Vol 3 No 6

On September 28, 2017, the FDA approved Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, as well as for use alone in patients whose metastatic breast cancer progressed after endocrine therapy and after previous use of chemotherapy in the metastatic setting.

“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approved Verzenio for these 2 uses based on clinical trials showing its benefits for patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The most common side effects with Verzenio are diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, and thrombocytopenia.

Share this:

Recommended For You
Issue IntroductionsBreast Cancer
A Word of Encouragement
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
As a breast cancer survivor herself, Ms. Shockney offers advice in hope of helping women diagnosed with breast cancer regain a sense of peace.
Breast CancerInterview with the Advocates
Young Survival Coalition: Focused on the Needs of Young Adults with Breast Cancer
By Kristin Siyahian
An interview with Jamie Larson of the Young Survival Coalition about the many programs their organization offers to young women with breast cancer.
Patient StoriesBreast Cancer
Our Future: “Good Girls” with Advanced Breast Cancer
By Elizabeth McSpadden
After being diagnosed with advanced breast cancer at age 30, Elizabeth McSpadden was shocked by the lack of appropriate norms to address fertility and other relevant issues in young women with cancer.
Last modified: June 10, 2022

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests